ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1434	National Cancer Institute	Html	en	Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.	CLL 0.563454 German CLL Study 0.551069 monoclonal B-cell lymphocytosis 0.528403 Engl J Med 0.555252 trial 0.525679 leukemia group 0.552678 M. Prolymphocytic leukemia 0.545972 Routine chronic administration 0.534661 lymphocytic leukemia patients 0.591222 Leukemia group B. 0.542105 CLL Study Group 0.54078 cyclophosphamide 0.529502 Byrd JC 0.527428 Keating MJ 0.535835 advanced chronic 0.539233 patients 0.592663 Lymphocytic Leukemia Study 0.593872 T-cell prolymphocytic leukemia 0.546745 refractory high-risk chronic 0.534243 refractory chronic 0.528565 Adult Leukemia Group 0.542021 Leuk Lymphoma 0.531402 Lymphocytic Leukemia section 0.595648 fludarabine 0.547348 alemtuzumab versus fludarabine 0.527105	untreated B chronic 0.530625 et al. 0.648755 treatment 0.535273 small lymphocytic lymphoma 0.590269 French Cooperative Group 0.528743 German Chronic Lymphocytic 0.583925 Relapsed Chronic Lymphocytic 0.579501 acute myeloid leukemia 0.53754 stem cell 0.529413 Leukemia Study Group 0.55235 rituximab 0.530116 fludarabine-refractory B-cell chronic 0.53547 CLL therapy 0.52689 chronic lymphoid leukemia 0.573599 CLL Study Group. 0.526303 Abstract 0.627578 therapy 0.53011 Clin Oncol 0.713099 hairy cell leukemia 0.553353 blood 0.56117 chronic lymphocytic leukemia 0.965039 chronic lymphocytic leukaemia 0.705583 previously untreated patients 0.578343 allogeneic stem cell 0.525551	CLICK HERE
1592	National Cancer Institute	Html	en	Thymoma and Thymic Carcinoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of thymoma and thymic carcinoma.	cancer treatment 0.359999 malignant tumor cells 0.342024 body 0.355156 type 0.305883 PDQ cancer information 0.433839 clinical trial search 0.425022 cancer cell 0.325256 thymic carcinoma cells 0.326827 clinical trials 0.988832 thymoma 0.371455 cancer information summary 0.383363 clinical trial 0.804071 patients 0.340124 earlier clinical trials 0.306378 thymic carcinoma spreads 0.306453 treatment clinical trial 0.327343 PDQ Adult Treatment 0.30754 NCI PDQ cancer 0.333099 radiation therapy 0.826788 Treatment Editorial Board 0.331284 thymic carcinomas 0.308782 General information 0.310597 general cancer information 0.312288 thymic carcinoma 0.970766 treatment 0.610928	new ways 0.369751 anticancer drugs 0.338472 new cancer treatments 0.318168 NCI-supported cancer 0.344007 cancer cells 0.453663 Cancer Information Service 0.312701 treatment clinical trials 0.363023 thymic carcinoma look 0.319623 National Cancer Institute 0.457133 tumor cells 0.34225 normal cells 0.313543 new treatment 0.393453 new combinations 0.333745 Blood. The cancer 0.306577 metastatic tumor 0.308755 PDQ summary 0.316304 cancer clinical trials 0.447345 stage 0.3338 tumor 0.364487 cancer information summaries 0.310618 comprehensive cancer information 0.311036 Thymic Carcinoma Treatment 0.323064 cancer 0.980046 standard treatment 0.319507	CLICK HERE
1633	National Cancer Institute	Html	en	Acupuncture (PDQ®)–Health Professional Version	Expert-reviewed information summary about acupuncture as a treatment for people with cancer or cancer-related disorders.	acupuncture group 0.544956 acupuncture point injection 0.56675 different acupuncture styles 0.557087 acupuncture treatment sessions 0.54489 acupuncture treatments. 0.545813 Hand Acupuncture Therapy 0.545719 acupuncture treatment groups 0.559928 acupuncture points 0.588119 acupuncture therapy 0.563015 traditional acupuncture 0.548268 acupuncture point 0.596123 laser acupuncture 0.537252 trigger point acupuncture 0.547942 Acupuncture treatment points 0.566499 auricular acupuncture 0.588794 hand acupuncture 0.553522 scalp acupuncture 0.536815 needle acupuncture treatment 0.563009 microwave acupuncture 0.542417 Tradit Chin Med 0.692529 French acupuncture 0.546506 acupuncture intervention 0.539071 acupuncture treatment 0.701699	I. Acupuncture 0.548929 cancer pain 0.545512 antiemetic acupuncture point 0.541836 acupuncture treatment group 0.55583 limited acupuncture treatment 0.578929 acupuncture practice 0.552272 acupuncture analgesia 0.53661 acupuncture techniques 0.555209 Acupuncture devices 0.538698 breast cancer survivors 0.59422 relevant acupuncture points 0.559867 Acupuncture stimulation enhances 0.541189 acupuncture 0.900284 acupuncture treatment protocol 0.543974 American medical acupuncture 0.557696 acupuncture needles 0.571268 acupuncture needle usage 0.544037 French energetic acupuncture 0.555749 hot flashes 0.662063 classical acupuncture techniques 0.547726 standard acupuncture treatment 0.552322 constitutional acupuncture 0.545774 nose acupuncture 0.536571	CLICK HERE
1844	National Cancer Institute	Html	es	Tratamiento del cáncer de vías biliares (colangiocarcinoma) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vías biliares.	adjuvant chemotherapy 0.497068 Compton CC 0.455578 adjuvant chemotherapy useful 0.462157 bile ducts 0.908316 bile duct carcinomas 0.774332 inoperable carcinoma 0.476348 intrahepatic cholangiocarcinoma 0.503925 Sin embargo 0.470784 Definiciones TNM 0.476617 numerosas series 0.506838 7th ed 0.45537 improves survival after 0.45137 resected pancreaticobiliary carcinoma 0.499622 biliary tract cancer 0.575176 Radiat Oncol Biol 0.701902 external beam 0.48514 vías biliares estadio 0.564018 extrahepatic bile ducts 0.466498 Combined external beam 0.45221 patients with 0.492787 gallbladder carcinoma 0.510432 postoperative adjuvant chemotherapy 0.462347 Distal bile duct 0.448596 M0 T1 0.473506 surgical resection 0.452719	M0 T4 0.484822 M0 T3 0.485565 external beam radiotherapy 0.453326 Estadio TNM Descripción 0.522095 preoperative biliary 0.453311 external beam irradiation 0.452128 hilar cholangiocarcinoma 0.689926 conducto biliar distal 0.669242 Cancer Staging Manual 0.512502 Carcinoma indiferenciado.Tipos 0.498115 Surg Oncol 0.46427 New York 0.449054 Is postoperative adjuvant 0.451387 clasificación tnm 0.471721 Oncol Biol Phys 0.711839 biliar extrahepático distal 0.924726 Byrd DR 0.452521 0a estadio tnm 0.528327 M0 Tis 0.527937 Am Coll Surg 0.467573 plus s-1 chemotherapy 0.455855 AJCC Cancer Staging 0.522691 Edge SB 0.455654 plus gemcitabine versus 0.449075	CLICK HERE
2108	National Cancer Institute	Html	es	Prevención del cáncer de esófago (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de esófago y sobre la investigación dirigida a la prevención de esta enfermedad.	Engel LS 0.373609 Lindgren A 0.36811 upper gastrointestinal tract 0.346284 Cancer Research Fund 0.36332 double-blind intervention study 0.424218 Lagergren J 0.644302 Overholt BF 0.373783 American Cancer Society 0.556588 gastroesophageal reflux 0.530195 pooled analysis from 0.437305 Spechler SJ 0.373642 Kerlikowske K 0.370938 Symptomatic gastroesophageal reflux 0.441142 Instituto Nacional 0.401102 adenocarcinoma after antireflux 0.427487 Krewski D 0.370088 Sharma P 0.368176 Bergström R 0.435333 Chow WH 0.372718 with dysplasia 0.373025 Estados Unidos 0.417008 Natl Cancer Inst 0.801603 multi-site case-control study 0.44183 PDQ Prevención 0.356958 esophageal adenocarcinoma 0.994739	intestinal metaplasia 0.38046 Goyal RK 0.374621 Population attributable risks 0.444629 Siemiatycki J 0.370746 SEER Cancer Statistics 0.366598 Murray LJ 0.372685 Corley DA 0.666943 Muñoz N 0.361794 Cancer Facts 0.35503 gastric cancers 0.376055 cigarette smoking 0.377492 Norman Barrett 0.429462 Bang LJ 0.364677 National Cancer Institute 0.444849 Cancer Research 0.391943 gastric carcinoma 0.350615 Verma R 0.369649 Esophageal Adenocarcinoma Consortium 0.593225 Vaughan TL 0.552829 oesophageal adenocarcinoma 0.415979 Radiofrequency ablation 0.374836 systematic review 0.372952 estudios cohortes 0.383438 Franco E 0.368432	CLICK HERE
3436	National Cancer Institute	Html	es	Prevención del cáncer de estómago (gástrico) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de estómago y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	accessed july 0.333514 Chiaradia G 0.316124 pylori eradication treatment 0.329538 accessed march 0.316023 Causes Control 0.327021 Cancer Statistics Review 0.449494 Sin embargo 0.352357 American Cancer Society 0.453658 gastric lesions with 0.314929 Straif K 0.314594 Instituto Nacional 0.319677 IARC Working Group 0.33075 PDQ Exámenes 0.315741 Estados Unidos 0.320311 Natl Cancer Inst 0.573491 Fifteen-year effects 0.315673 biological agents 0.352496 PDQ Prevención 0.315154 gastric cancer incidence 0.458115 updated meta-analysis 0.316823 Nogueira A 0.314785 Cancer Epidemiology 0.329476 European Prospective Investigation 0.328359 Cancer Society Award 0.332676 SEER Cancer Statistics 0.452207	Prospective Investigation Into 0.328734 Lancet Oncol 0.334048 Smoking status 0.321406 gástrico versus 0.335 hombres fumadores 0.333574 Gianfagna F 0.314457 Taylor PR 0.32208 from cancer incidence 0.333557 Cancer Facts 0.332084 Carcinogenic Risks 0.316292 mujeres fumadoras 0.315366 Bouvard V 0.314729 Helicobacter pylori 0.513706 Pereira AK 0.315186 National Cancer Institute 0.508441 antiguos fumadores 0.3326 consumo escaso 0.318979 Investigation Into Cancer 0.373898 Pera G 0.315038 gastric cancer 0.937774 anti-helicobacter pylori therapy 0.32551 systematic review 0.331147 helicobacter pylori eradication 0.395224 Krapcho M 0.325661	CLICK HERE
3460	National Cancer Institute	Html	es	Coenzima Q10 (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con cáncer.	Natl Acad Sci 0.506232 animal models 0.503048 Lockwood K 0.522246 Friend leukemia virus 0.50335 Mol Aspects Med 0.525442 Prog Drug Res 0.505422 Exp Clin Res 0.507107 Ernster L 0.506157 Clin Investig 0.504327 vitamina q10 0.508703 vitamin q10 0.549224 Health Syst Pharm 0.503499 Chem Pathol Pharmacol 0.515808 Bliznakov EG 0.512562 Hanioka T 0.504235 coenzyme q10 0.845306 with vitamin q10 0.522905 reticuloendothelial system upon 0.50329 Res Commun Chem 0.525595 coenzima q10 0.990386 Nylander M 0.503126 system upon stimulation 0.503357 coenzima q.10 0.50372 Coenzyme Q10 administration 0.515239 patients with 0.52239	Clinical Aspects 0.506167 Folkers K 0.720923 patients treated with 0.503528 Osterborg A 0.503093 coenzima q10 resumen 0.509859 Commun Chem Pathol 0.52121 Moesgaard S 0.509545 Biophys Res Commun 0.66246 Chemother Rep 0.503476 Nordenbrand K 0.502764 Proc Natl Acad 0.506461 Apparent partial remission 0.503092 Biochem Biophys Res 0.653978 with nutritional antioxidants 0.504649 coenzima q10 ayuda 0.51293 Drugs Exp Clin 0.50459 conzima q10 0.506965 Overvad K 0.504381 Clin Nutr 0.503026 serious deficiency 0.503488 coenzyme q10 concentrations 0.523415 radicales libres 0.504036 essential fatty acids 0.503269 Yamashita S 0.503124	CLICK HERE
16837	National Cancer Institute	Html	en	Stanford University — Cancer Translational Nanotechnology Training Program	The focus of the Stanford University Cancer Nanotechnology Training Center is presented here.	interdisciplinary leaders 0.696815 program director 0.689314 nanoengineering 0.558309 M.D. 0.531791 molecular imaging 0.829201 faculty 0.529401 3-year program 0.755923 proposed 5-year cycle 0.860016 Ph.D. 0.531868 skill sets 0.677497 trainee progress 0.671123 Stanford Cancer-Translational Nanotechnology 0.898203 cancer immunology 0.705615 molecular pharmacology 0.687504 gene therapy 0.664625 cross-disciplinary training 0.726482 complementary mentors 0.683687 coursework 0.53863 biochips 0.551532 Stanford CNTC website 0.833637 interdisciplinary researchers 0.692233 molecular biology 0.695814 Jianghong Rao 0.719515 electrical engineering 0.669775	grant application process 0.806404 cancer research 0.843254 research advisor 0.68327 Advisory Committee 0.662141 Stanford Oncology Clinical 0.845549 National Cancer Institute 0.835301 Principal Investigator 0.706879 postdoctoral trainees 0.850619 Dean Felsher 0.699264 Training Committee 0.688222 clinical translation 0.702935 materials science 0.66948 nanomedicine 0.549348 3-year training program 0.964337 hands-on training activities 0.833884 clinical component 0.680058 bioengineering 0.539755 cancer nanotechnology translation 0.891967 Lecture Series 0.660584 clinical cancer medicine 0.877908 entire program 0.674038 Training Focus 0.735031 cancer biology 0.706458 mock grant proposal 0.812529	CLICK HERE
16842	National Cancer Institute	Html	en	Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research	The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here.	predoctoral fellows 0.736483 cancer nanobiotechnology 0.632531 optimal treatment 0.545276 Johns Hopkins University 0.729715 journal club 0.539106 novel cancer diagnostics 0.713403 program fosters 0.562779 steady state number 0.670018 epigenetic markers 0.560601 tumor boards 0.538166 NTCR program 0.576419 new frontier 0.564875 individual patient 0.643505 engineering/physics discipline 0.563571 physical sciences-oncology center 0.676488 lab course 0.540911 new modalities 0.563 cellular / cancer 0.59221 Johns Hopkins Institute 0.669855 dedicated annual symposium 0.651728 experimental facilities 0.538368 Vivo Cellular 0.548936 Molecular Imaging Center 0.688968 black-box input-output techniques 0.710638	scientific exploration 0.554225 clinical resources 0.5443 human diseases 0.555299 cancer cell functions 0.720912 clinical conferences 0.540551 high-throughput diagnostic tools 0.682779 non-viral delivery systems 0.686087 unique educational resources 0.657197 postdoctoral fellows 0.715577 Principal Investigator 0.564913 therapeutic tools 0.551025 Pancreatic Cancer Center 0.731915 Ludwick Center 0.581555 NTCR trainees 0.59515 cancer nanotechnology excellence 0.742492 outstanding trainees 0.578764 disease phenotype 0.55677 Comprehensive Cancer Center 0.727928 Cancer Genetics 0.585039 NTCR fellows 0.742981 engineer novel drug/antibody/siRNA 0.668859 human cancers 0.551276 core courses 0.541397 Training Focus 0.565904	CLICK HERE
16854	National Cancer Institute	Html	null	Step 4: NCI Funding Determinations	Funding determinations are made around Oct. 1 each federal fiscal year. These decisions take into account several factors, including Congressional mandates, new scientific opportunities and program priorities when deciding which grants receive funding.			CLICK HERE